In short
Clinical trials investigating ULEFNERSEN are studying its use in people with amyotrophic lateral sclerosis linked to FUS mutations. The trials are designed to assess efficacy, safety, pharmacokinetics, pharmacodynamics, and survival-related outcomes in this target group. They focus on how participants function over time and when rescue treatment may be needed.
Key points
- Clinical trials investigating ULEFNERSEN are focused on people with amyotrophic lateral sclerosis linked to FUS mutations, also called FUS-ALS. The available trial is a Phase 4 interventional study with 95 planned participants and is listed as authorised. Researchers are evaluating efficacy, safety, pharmacokinetics, and pharmacodynamics, with a strong focus on clinical function and survival. The main measurements include ALSFRS-R functional score, time to rescue treatment, and ventilation assistance-free survival. The study is designed to see whether ULEFNERSEN can help slow worsening in this specific ALS group.
Trial overview
The available trial for ULEFNERSEN is titled A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS). It is an interventional study, which means researchers are giving a study treatment and comparing outcomes over time. The trial is authorised and plans to enroll 95 participants.
Who is being studied
This trial focuses on people with amyotrophic lateral sclerosis, also called ALS, who have FUS mutations. The condition is described in the trial as amyotrophic lateral sclerosis with fused in sarcoma mutations, or FUS-ALS. This means the study is not for all ALS patients, but for a specific genetic group.
The trial data do not list detailed inclusion or exclusion rules beyond the FUS-ALS population. Because of that, the exact participation rules are not fully shown in the source provided.
What researchers measure
The main goal is to evaluate the effects of ULEFNERSEN versus placebo on functional impairment, which means how much the disease affects daily ability. Researchers use the ALSFRS-R, a scale with 12 questions and a total score from 0 to 48, where higher scores mean better function. The scale looks at bulbar function, gross motor skills, fine motor skills, and respiratory function.
The trial also measures time of rescue. In this study, rescue can happen if a participant’s ALSFRS-R total score falls below 15 and drops by at least 10 points from baseline at Study Day 253 or later, and the change is confirmed after at least 4 weeks. If rescue happens, the participant may stop Part 1 and enter Part 2 of the study.
Another key outcome is ventilation assistance-free survival, shortened to VAFS. This means the time until either death or permanent ventilation, which is defined in the trial as more than 22 hours of mechanical ventilation per day for more than 21 consecutive days without an acute reversible event.
The study title also states that researchers are evaluating safety, pharmacokinetics, and pharmacodynamics. In simple terms, pharmacokinetics means how the body handles the treatment, and pharmacodynamics means what the treatment does in the body.
Study design and treatment groups
The trial compares ULEFNERSEN with placebo, which is a look-alike treatment without the active study drug. The intervention list shows intrathecal use, which means the study treatment is given into the fluid around the spinal cord.
The source also notes two parts of the study, with Part 1 using the joint rank analysis of ALSFRS-R outcomes and rescue-related measures. The trial data do not provide a full breakdown of all study procedures, but they do show that the design includes follow-up over time and comparison against placebo.
Trial phase and status
The study is listed as Phase 4. Phase 4 trials are later-stage studies that look at how a treatment performs in a clinical setting after earlier development work. The current status is Authorised.
The enrollment target is 95 participants. This size suggests a focused study in a specific patient group rather than a very large population.
What the trial results mean for patients
This trial is trying to learn whether ULEFNERSEN can help people with FUS-ALS keep better function for longer and delay major worsening. The main patient-centered outcomes are everyday function, the need for rescue treatment, and survival without permanent breathing support.
Because the trial is focused on a specific genetic form of ALS, its results may be most relevant to people with FUS mutations rather than all people with ALS. The available source gives a clear picture of the study’s goals, but not all detailed eligibility rules or all visit procedures.